{"nctId":"NCT01047553","briefTitle":"Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients","startDateStruct":{"date":"2009-12"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":251,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Formoterol (OT)"]}],"interventions":[{"name":"Formoterol (OT)","otherNames":["Oxis Turbuhaler®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatients, men or women ≥ 40 years\n* A clinical diagnosis of COPD according to guidelines, and current COPD symptoms.\n* Post-bronchodilator FEV1 \\< 80% of predicted normal value and FEV1/FVC \\< 70%, post-bronchodilator\n\nExclusion Criteria:\n\n* A history and/or current clinical diagnosis of asthma and atopic diseases such as Allergic rhinitis\n* Patients who have experienced COPD exacerbation requiring at least one of the following treatment, hospitalisation and/or a course of systemic steroid within 4 weeks prior to the study start.\n* Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart failure, uncontrolled hypertension as defined by the investigator, or any other relevant cardiovascular disorder as judged by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Erythrocytes","description":"Mean change from Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.25","spread":"23.8"},{"groupId":"OG001","value":"-5.2","spread":"27.5"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Haemoglobin","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.29","spread":"0.73"},{"groupId":"OG001","value":"-0.20","spread":"1.14"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology-Leucocytes","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-132.1","spread":"1535.3"},{"groupId":"OG001","value":"-289.5","spread":"1284.6"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology-Platelet Count","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"3.29"},{"groupId":"OG001","value":"-0.40","spread":"4.06"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology Eosinophils","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":"2.21"},{"groupId":"OG001","value":"0.45","spread":"2.45"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology Basophil","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.37"},{"groupId":"OG001","value":"0.01","spread":"0.35"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology-Lymphocytes","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.31","spread":"7.86"},{"groupId":"OG001","value":"-0.43","spread":"7.06"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology-Monocytes","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"1.55"},{"groupId":"OG001","value":"-0.03","spread":"1.49"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Haematology -Neutrophils","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.92","spread":"8.32"},{"groupId":"OG001","value":"-0.28","spread":"7.64"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"10.0"},{"groupId":"OG001","value":"4.9","spread":"65.9"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"12.0"},{"groupId":"OG001","value":"2.6","spread":"39.3"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"44.7"},{"groupId":"OG001","value":"-4.4","spread":"52.9"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Creatinine","description":"Change from Baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.009","spread":"0.089"},{"groupId":"OG001","value":"0.021","spread":"0.117"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.22"},{"groupId":"OG001","value":"0.02","spread":"0.19"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Sodium","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.9"},{"groupId":"OG001","value":"-0.2","spread":"2.0"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Potassium","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.15","spread":"0.34"},{"groupId":"OG001","value":"-0.07","spread":"0.37"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S- Calcium","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.42"},{"groupId":"OG001","value":"-0.03","spread":"0.35"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Albumin","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.28"},{"groupId":"OG001","value":"0.00","spread":"0.23"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry-S-Total Protein","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.40"},{"groupId":"OG001","value":"-0.09","spread":"0.37"}]}]}]},{"type":"PRIMARY","title":"Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":"4.00"},{"groupId":"OG001","value":"0.07","spread":"3.99"}]}]}]},{"type":"PRIMARY","title":"Vital Signs- Sitting SBP","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"14.8"},{"groupId":"OG001","value":"-2.1","spread":"16.4"}]}]}]},{"type":"PRIMARY","title":"Vital Signs- Sitting DBP","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"8.9"},{"groupId":"OG001","value":"-3.5","spread":"10.1"}]}]}]},{"type":"PRIMARY","title":"Vital Signs - Pulse Rate","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"10.7"},{"groupId":"OG001","value":"-0.1","spread":"10.2"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - Heart Rate","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"11.4"},{"groupId":"OG001","value":"0.6","spread":"12.0"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - QT Interval","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"22.8"},{"groupId":"OG001","value":"2.6","spread":"26.7"}]}]}]},{"type":"PRIMARY","title":"ECG Variables - QTcB Interval","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"20.6"},{"groupId":"OG001","value":"1.2","spread":"22.2"}]}]}]},{"type":"PRIMARY","title":"ECG Variables QTcF Interval","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"15.1"},{"groupId":"OG001","value":"1.7","spread":"19.1"}]}]}]},{"type":"PRIMARY","title":"ECG Variables RR Interval","description":"Change from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.1","spread":"7.2"},{"groupId":"OG001","value":"131.7","spread":"124.1"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in One Second (FEV1)","description":"The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.46","spread":null},{"groupId":"OG001","value":"99.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Forced Vital Capacity (FVC)","description":"The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.62","spread":null},{"groupId":"OG001","value":"99.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Morning Peak Expiratory Flow(PEF)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"34.9"},{"groupId":"OG001","value":"7.3","spread":"26.2"}]}]}]},{"type":"SECONDARY","title":"Evening Peak Expiratory Flow (PEF)","description":"The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"34.0"},{"groupId":"OG001","value":"7.9","spread":"28.2"}]}]}]},{"type":"SECONDARY","title":"Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"-0.2","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms","description":"There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.8"},{"groupId":"OG001","value":"-0.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score","description":"The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"1.2"},{"groupId":"OG001","value":"-0.4","spread":"1.4"}]}]}]},{"type":"SECONDARY","title":"Number of COPD Exacerbations Over the Treatment Period","description":"A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Use of SABA (Salbutamol) as Reliever Medication","description":"The change from Run-in period average to Treatment period average for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.7"},{"groupId":"OG001","value":"0.0","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"St George's Respiratory Questionnaire (SGRQ) Total Score","description":"SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.34","spread":"8.48"},{"groupId":"OG001","value":"-0.57","spread":"7.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":125},"commonTop":["NASOPHARYNGITIS","Back Pain","Chronic Obstructive Pulmonary Disease","Bronchitis","Pneumonia"]}}}